Cyramza is a monoclonal antibody used to treat several types of advanced cancer by targeting the vascular endothelial growth factor receptor 2 (VEGFR2).
: Advanced or metastatic gastric or gastroesophageal junction adenocarcinoma, metastatic non-small cell lung cancer, and hepatocellular carcinoma. 125477
The number most prominently refers to BLA 125477 , the official Biologics License Application number for the FDA-approved drug Cyramza (ramucirumab) . Pharmaceutical Context (Cyramza) Cyramza is a monoclonal antibody used to treat
: The original approval for gastric cancer occurred in April 2014 . Other References metastatic non-small cell lung cancer